COPD Drugs Linked To Increased Cardiovascular Health Risks: Study

The use of some drugs that treat chronic obstructive pulmonary disease (COPD), such as Serevent and Symbicort, may increase the risk of heart problems after just one month of regular use, according to the findings of a new study. 

Researchers from Taiwan report that some COPD treatments are linked with a 1.5-fold increased cardiovascular risk after just 30 days of use. The findings were published on January 2 in the medical journal JAMA Internal Medicine.

The study looked at initial use and new use of inhaled long-acting β2-agonists (LABAs) or antimuscarinic antagonists (LAMAs) among more than 280,000 patients with COPD in Taiwan from 2007 to 2011. LABAs include brands such as Foradil, Serevent, Symbicort, AirDuo, and Advair Diskus. LAMAs include brands such as Spiriva, the Ultibro Breezhaler, and Tudorza Pressair.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to the findings, new use of either class of medication was linked with a 1.5-fold increased risk of cardiovascular disease within 30 days of initiation. Neither the type of drug nor whether it was inhaled or taken in pill form appeared to make to make a difference in regard to the overall risks. The researchers indicated the risk also did not differ based on the patient’s heart disease history or other risk factors.

“New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations,” the researchers concluded.

The findings came just two weeks after the FDA announced it was removing a boxed warning from other LABAs in combination with inhaled corticosteroids which indicated that they carried an increased risk of death. However, the FDA also noted that using long-acting beta agonists alone for the treatment of lung inflammation is still associated with an increased risk of asthma-related death, and a black box warning about those risks will remain in place for all single-ingredient LABA medications.

COPD is a chronic inflammatory lung disease that causes the airflow from the lungs to become blocked. It is also an umbrella term for several chronic lung conditions, such as bronchitis and emphysema. People with COPD often experience persistent cough, mucus, shortness of breath, and chest tightness.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks
Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks (Posted 2 days ago)

Women who used Johnson's Baby Powder around their genitals for feminine hygiene purposes now live in fear of developing ovarian cancer, according to the class action lawsuit seeking medical monitoring for future diagnoses

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted 3 days ago)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.